Table 5.
The predictive value of PCDH8 methylation for the five-year overall survival in non muscle invasive bladder cancer (n = 233)
| Variable |
Univariate analysis |
Multivariate analysis |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| PCDH8 methylation (M vs. U) |
4.653 |
1.237-7.314 |
<0.0001 |
3.017 |
1.542-8.251 |
0.0015 |
| Age (>65 vs. ≦65) |
1.135 |
0.779-6.273 |
0.3471 |
|
|
|
| Sex (Male vs. Female) |
0.874 |
0.645-3.228 |
0.7361 |
|
|
|
| Number (Multiple vs. Single) |
1.054 |
0.798-6.417 |
0.3784 |
|
|
|
| Size (>3 cm vs. ≤3 cm) |
1.253 |
0.913-10.257 |
0.3095 |
|
|
|
| Grade (G3 vs. G1 / G2) |
3.876 |
1.643-6.024 |
0.0021 |
1.852 |
1.144-5.964 |
0.0324 |
| Stage (T1 vs. Ta) | 1.015 | 0.792-7.572 | 0.4338 | |||
HR: Hazard Ratio; M: Methylated; U: Unmethylated.